14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
The Supreme Court of the United States, on writ of certiorari in Dutra Group v. Christopher Batterto...
Read More >
Most employers with more than 10 employees are required to keep a record of serious work-related inj...
Read More >
USDOL has announced a proposed rule intended to clarify the "fluctuating workweek" under the FLSA. T...
Read More >
This month we're taking a break from updates on emerging employment law issues. Let's take a moment ...
Read More >
Perhaps it’s not quite business as usual after all. Last week we reported that the Office of Feder...
Read More >
This issue covers important, developing areas of Delaware corporation law and deal litigation, inclu...
Read More >